1. Home
  2. ZYME vs PNTG Comparison

ZYME vs PNTG Comparison

Compare ZYME & PNTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYME
  • PNTG
  • Stock Information
  • Founded
  • ZYME 2003
  • PNTG 2019
  • Country
  • ZYME United States
  • PNTG United States
  • Employees
  • ZYME N/A
  • PNTG N/A
  • Industry
  • ZYME Biotechnology: Pharmaceutical Preparations
  • PNTG Medical/Nursing Services
  • Sector
  • ZYME Health Care
  • PNTG Health Care
  • Exchange
  • ZYME Nasdaq
  • PNTG Nasdaq
  • Market Cap
  • ZYME 968.5M
  • PNTG 829.8M
  • IPO Year
  • ZYME 2017
  • PNTG N/A
  • Fundamental
  • Price
  • ZYME $15.93
  • PNTG $25.20
  • Analyst Decision
  • ZYME Buy
  • PNTG Buy
  • Analyst Count
  • ZYME 7
  • PNTG 6
  • Target Price
  • ZYME $20.00
  • PNTG $35.00
  • AVG Volume (30 Days)
  • ZYME 446.6K
  • PNTG 353.2K
  • Earning Date
  • ZYME 10-30-2025
  • PNTG 11-05-2025
  • Dividend Yield
  • ZYME N/A
  • PNTG N/A
  • EPS Growth
  • ZYME N/A
  • PNTG 20.56
  • EPS
  • ZYME N/A
  • PNTG 0.77
  • Revenue
  • ZYME $122,867,000.00
  • PNTG $798,923,000.00
  • Revenue This Year
  • ZYME $107.76
  • PNTG $28.29
  • Revenue Next Year
  • ZYME $2.35
  • PNTG $11.61
  • P/E Ratio
  • ZYME N/A
  • PNTG $32.78
  • Revenue Growth
  • ZYME 95.94
  • PNTG 30.58
  • 52 Week Low
  • ZYME $9.03
  • PNTG $21.18
  • 52 Week High
  • ZYME $17.70
  • PNTG $37.13
  • Technical
  • Relative Strength Index (RSI)
  • ZYME 64.90
  • PNTG 54.16
  • Support Level
  • ZYME $14.88
  • PNTG $23.68
  • Resistance Level
  • ZYME $16.37
  • PNTG $26.11
  • Average True Range (ATR)
  • ZYME 0.65
  • PNTG 0.80
  • MACD
  • ZYME 0.11
  • PNTG 0.12
  • Stochastic Oscillator
  • ZYME 84.12
  • PNTG 63.01

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About PNTG The Pennant Group Inc.

Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.

Share on Social Networks: